Home › Companies › IMVT

Immunovant, Inc.

IMVT Rare disease Lead: Phase 2 4 Biotech Distilled articles ↓

Immunology Neurology Protein

Most recent annual filing: 2026-05-20

Pipeline (6 active programs)

IMVT-1402

Protein Target: FcRn

Graves' Disease Phase 2 subcutaneous
Rheumatoid Arthritis Phase 2 subcutaneous
Myasthenia Gravis Phase 2 subcutaneous
Chronic Inflammatory Demyelinating Polyneuropathy Phase 2 subcutaneous
Sjögren's Disease Phase 2 subcutaneous
Cutaneous Lupus Erythematosus Phase 2 subcutaneous

Discontinued (1)

batoclimab — undisclosed · Company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402

Biotech Distilled coverage (4)

2026-05-20 UPDATE: Immunovant (IMVT) - The Bio-Better Bet Cashes Its First Check 🔒 Paid
2026-04-04 UPDATE: Immunovant (IMVT) - The Bato Swan Song and the Pivot to Purity 🔒 Paid
2026-02-07 UPDATE: Immunovant (IMVT) - Quarterly Update 🔒 Paid
2026-02-02 Immunovant (IMVT): Scientific Deep Dive for IMVT-1402 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.